90,503 Shares in scPharmaceuticals, Inc. $SCPH Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired a new position in scPharmaceuticals, purchasing 90,503 shares valued at approximately $238,000, increasing its ownership to about 0.18% of the company.
• Several institutional investors, including Rice Hall James & Associates LLC and BNP Paribas Financial Markets, have significantly increased their holdings in scPharmaceuticals, illustrating growing confidence in the stock.
• Analyst sentiment is mixed, with multiple upgrades and downgrades leading to a consensus rating of "Hold" and a price target of $7.78, despite the company reporting a loss of $0.34 EPS last quarter.

Nuveen LLC acquired a new position in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 90,503 shares of the company's stock, valued at approximately $238,000. Nuveen LLC owned about 0.18% of scPharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SCPH. Rice Hall James & Associates LLC raised its holdings in scPharmaceuticals by 41.3% during the first quarter. Rice Hall James & Associates LLC now owns 1,398,057 shares of the company's stock worth $3,677,000 after purchasing an additional 408,422 shares during the last quarter. King Luther Capital Management Corp raised its holdings in scPharmaceuticals by 9.2% during the first quarter. King Luther Capital Management Corp now owns 3,121,170 shares of the company's stock worth $8,209,000 after purchasing an additional 263,260 shares during the last quarter. Raymond James Financial Inc. purchased a new position in scPharmaceuticals during the fourth quarter worth $318,000. BNP Paribas Financial Markets increased its position in scPharmaceuticals by 1,393.1% during the fourth quarter. BNP Paribas Financial Markets now owns 85,900 shares of the company's stock worth $304,000 after buying an additional 80,147 shares in the last quarter. Finally, Northern Trust Corp increased its position in scPharmaceuticals by 27.1% during the fourth quarter. Northern Trust Corp now owns 324,226 shares of the company's stock worth $1,148,000 after buying an additional 69,092 shares in the last quarter. 89.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Maxim Group downgraded scPharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 25th. Craig Hallum downgraded scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 price target for the company. in a research report on Monday, August 25th. Wall Street Zen raised scPharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, HC Wainwright downgraded scPharmaceuticals from a "strong-buy" rating to a "hold" rating and set a $5.35 price target for the company. in a research report on Friday, August 29th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $7.78.

scPharmaceuticals Price Performance

Shares of NASDAQ:SCPH opened at $5.57 on Friday. The company has a market cap of $296.88 million, a P/E ratio of -3.08 and a beta of 0.35. The company has a quick ratio of 3.14, a current ratio of 3.85 and a debt-to-equity ratio of 3.86. scPharmaceuticals, Inc. has a 52 week low of $1.94 and a 52 week high of $6.28. The business has a fifty day simple moving average of $4.91 and a 200-day simple moving average of $3.71.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). The business had revenue of $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. Equities research analysts forecast that scPharmaceuticals, Inc. will post -1.53 EPS for the current year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.